

XX (UROC-) UROGENESYS INC.
 PA Hubert RS, Raitano AB, Afar DEH, Mitchell SC, Paris M;
 PI Jakobovits A;
 PI WPI: 2001-308685/32.
 DR P-PSDB: AA02211.
 DR
 XX Detecting cancers, particularly of prostate and colon, from
 PT overexpression of SGP28 protein, also methods for treating these
 PT cancers e.g. by vaccination with the protein
 PS Claim 16: Page 62-63; 102pp; English.
 XX
 CC The present invention relates to methods and compositions for the
 CC diagnosis and therapy of prostate cancer which utilize human SGP28
 CC (specific granule protein 28) gene and proteins. The method involves
 CC detecting cancers, particularly of prostate and colon, from
 CC overexpression of SGP28 protein. The expression of SGP28, which is an
 CC extracellular protein is restricted to the prostate and ovary, and is
 CC markedly up-regulated in prostate tumours. SGP28 sequence is used for
 CC diagnosis (including in vivo imaging), staging, monitoring and prognosis
 CC of prostate and colon cancer, and for assisting selection of therapy.
 CC Also SGP28 expressing cancers can be treated by administering a
 CC composition or vaccine that contains a vector expressing an antibody
 CC specific for SGP28 protein, nucleic acid encoding SGP28 protein or its
 CC fragments, polypeptides encoded by SGP28 gene and SGP28-specific antibody
 CC is also used as source of therapeutic antisense or ribozyme agents, as
 CC primers/probes for diagnosis or prognosis, to identify compounds that
 CC inhibit calcium entry into prostatic cells, for recombinant production
 CC of SGP28 peptides and for isolating related sequences. SGP28 protein and
 CC its fragments are used to raise specific antibodies (Ab) and to identify
 CC specific binding agents (potentially useful as therapeutic and
 CC diagnostic agents) and also potential anticancer agents. The present
 CC sequence is human full-length 36163/SGP28 cDNA.
 CC
 XX
 XX Sequence 2144 BP; 735 A; 403 C; 382 G; 624 T; 0 other;
 S0
 Query Match 100.0%; Score 2144; DB 22; Length 2144;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2144; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 421 TAGGGCCAAAGACTCCCAAGCCAGTGGTGGACATTATACAGAGTTGGTACTCTT 480
 QY CATACCTCGTTGGATGGAATGCTACTGTCCTCAATCAAAAGTCTAAATACTACT 540
 DB 481 CATACCTCGTTGGATGGAATGCTACTGTCCTCAATCAAAAGTCTAAATACTACT 540
 QY 541 ATGTTGCCAATATGTCCTGCTGTAATGAGGCTAATAGACTATATGCTTATGAC 600
 DB 541 ATGTTGCCAATATGTCCTGCTGTAATGAGGCTAATAGACTATATGCTTATGAC 600
 QY 601 AAGAGCACCCTTGCCAGTGGCCCAATATCTGACAGTGGACTATGCCAATGGTT 660
 DB 601 AAGAGCACCCTTGCCAGTGGCCCAATATCTGACAGTGGACTATGCCAATGGTT 660
 QY 661 GCAAGTACGAAGATCTATATAGTAACTGTAAGTGAAGCTCACATTAACCTGTAAC 720
 DB 661 GCAAGTACGAAGATCTATATAGTAACTGTAAGTGAAGCTCACATTAACCTGTAAC 720
 QY 721 ATCAGTTGGTCAGGAGAGTGGCAAGGATCCTGCAATGTTTCAAGCATTATTTAA 780
 DB 721 ATCAGTTGGTCAGGAGAGTGGCAAGGATCCTGCAATGTTTCAAGCATTATTTAA 780
 QY 781 TACCATTTACACCCGAGTAGGCTATGTAGAGAGAGTCAATATCTACTTATGATTG 840
 DB 781 TACCATTTACACCCGAGTAGGCTATGTAGAGAGAGTCAATATCTACTTATGATTG 840
 QY 841 GCATCTCTTATGATTTATACATATATCTAGCTGAGAAATTTGAGGATGTTGATACAT 900
 DB 841 GCATCTCTTATGATTTATACATATATCTAGCTGAGAAATTTGAGGATGTTGATACAT 900
 QY 901 TGATTTCAAAATGTTTCTCTGATGCTGCTTTTATTTACAAAATATTTTTCATACA 960
 DB 901 TGATTTCAAAATGTTTCTCTGATGCTGCTTTTATTTACAAAATATTTTTCATACA 960
 QY 961 AATGTTTAAAAAGAACAAATCTATACAACTTGGATTTTATATATAAATCTTG 1020
 DB 961 AATGTTTAAAAAGAACAAATCTATACAACTTGGATTTTATATATAAATCTTG 1020
 QY 1021 TGATTTAAATTTACTGATTTAATAGGGAATTTGAAATTTGAAATTTGATTCATATGA 1080
 DB 1021 TGATTTAAATTTACTGATTTAATAGGGAATTTGAAATTTGAAATTTGATTCATATGA 1080
 QY 1081 CTAAATTCACATAAACCCTGATGGAAGTGAATATATGTTCTCTAGAACAAATGTACA 1140
 DB 1081 CTAAATTCACATAAACCCTGATGGAAGTGAATATATGTTCTCTAGAACAAATGTACA 1140
 QY 1141 AAAAGAACATATATATTTTACATGAACCTTGCTGATGCTTCTTCTAGCTCACT 1200
 DB 1141 AAAAGAACATATATATTTTACATGAACCTTGCTGATGCTTCTTCTAGCTCACT 1200
 QY 1201 CTAAAGCTAAGCATCTTCAAAAGCTTTTCCCATATGCTGCTTAATCTTTTACATCAT 1260
 DB 1201 CTAAAGCTAAGCATCTTCAAAAGCTTTTCCCATATGCTGCTTAAATCTTTTACATCAT 1260
 QY 1261 TCACCTTCTTCCCAATCATCTGCTGCAATCCACAAATGGAATGAGCTGCTCTCC 1320
 DB 1261 TCACCTTCTTCCCAATCATCTGCTGCAATCCACAAATGGAATGAGCTGCTCTCC 1320
 QY 1321 TAAACAATCTGCTGCTTTTATTTTGGCCAAATCAATACATCTTTGAATTTTATCTG 1380
 DB 1321 TAAACAATCTGCTGCTTTTATTTTGGCCAAATCAATACATCTTTGAATTTTATCTG 1380
 QY 1381 CATATAATTTTACATAGATATGATCAAAACCTTATTTTAAACCTCTCTCTCTTGAC 1440
 DB 1381 CATATAATTTTACATAGATATGATCAAAACCTTATTTTAAACCTCTCTCTCTTGAC 1440
 QY 1441 AAAAATCTCTTAAAAAAGATACAGATATATAGTAAATACCTCTCAAGAGAGT 1500
 DB 1441 AAAAATCTCTTAAAAAAGATACAGATATATAGTAAATACCTCTCAAGAGAGT 1500
 QY 1501 AGAATCTAGTCTCTCTCTCTGATGCTTCACTAAATCAAGTACTACTTCCAAAGAGT 1560
 DB 1501 AGAATCTAGTCTCTCTCTCTGATGCTTCACTAAATCAAGTACTACTTCCAAAGAGT 1560

RESULT 2	
AAH98651	
ID	AAH98651 standard; cDNA, 2133 BP.
XX	
AC	AAH98651.
XX	
DT	12-OCT-2001 (first entry)
XX	
DE	Human EST-derived coding sequence SEQ ID NO: 508.
XX	
KM	Human; sheep; pig; cow; fruit fly; yeast; hamster; macaque; horse;
KW	tomato; monkey; dog; sea urchin; expressed sequence tag; EST;
KX	diagnostics; forensic test; gene mapping; genetic disorder;
KM	biodiversity; gene therapy; nutrition; ss.
XX	
OS	Homo sapiens.
XX	
PN	W0200154477-A2.
XX	
PD	02-AUG-2001.
XX	
PF	25-JAN-2001; 2001MO-US02687.
XX	
PR	25-JAN-2000; 2000US-0491404.
PR	17-JUL-2000; 2000US-0617746.
PR	03-AUG-2000; 2000US-0631451.
PR	15-SEP-2000; 2000US-0663870.
XX	
PA	(HYSE-) HYSEQ INC.
XX	

	Query Match	99.2% Best Local Similarity	Score 1216.6	DB 22	Length 2133
	Matches 2129	Conservative	0	Mismatches	4
				Indels	0
				Gaps	0
QY	2	GATGAACAATACTTCATCTCTGCTGGAAACCACTGCATGACATTATCCAGTCT	61		
Db	1	GATGAACAATACTTCATCTCTGCTGGAAACCACTGCATGACATTATCCAGTCT	60		
QY	62	GTTGTCTCTGCTGCTGGGCTGCTCCANCTTTTCACCAATGSAAGATTAAGATCCGC	121		
Db	61	GTTGTCTCTGCTGCTGGGCTGCTCCATCTTTTCACCAATGSAAGATTAAGATCCGC	120		
QY	122	TTTTACTGCTTTGTTAAACCCCAACACAAAGTGCMAAGGAGATTGTGAATTAACACAA	181		
Db	121	TTTTACTGCTTTGTTAAACCCCAACACAAAGTGCMAAGGAGATTGTGAATTAACACAA	180		
QY	182	TGAAGTGAAGAGACAGTATCTCCCTCCGCCAGAAACACTGTCGAAGATGGAATGGAACA	241		
Db	181	TGAAGTGAAGAGAGAGTATCTCCCTCCGCCAGAAACACTGTCGAAGATGGAATGGAACA	240		
QY	242	AGAGCTCAGCAATATGCCAAAGTGGGCAACACAGTGCATTTACAGACAGTAAACC	301		
Db	241	AGAGCTCAGCAATATGCCAAAGTGGGCAACACAGTGCATTTACAGACAGTAAACC	300		
QY	302	AAAGATGCAATGACAACTCTTAAATGTGTGAGATCTCTCATGTCAAGTCCGCCAG	361		
Db	301	AAAGATGCAATGACAACTCTTAAATGTGTGAGATCTCTCATGTCAAGTCCGCCAG	360		
QY	362	CTCATGTGTACACAGCAATCCAAAGCTGGTTGATGAGTACAAATGATTTTGACTTTGGTCT	421		
Db	361	CTCATGTGTACACAGCAATCCAAAGCTGGTTGATGAGTACAAATGATTTTGACTTTGGTCT	420		
QY	422	AGGGCCAAAGACTCCCAACGAGTGGTGGAAATTTATACAGGTTGTTTGGTACTCTTC	481		
Db	421	AGGGCCAAAGACTCCCAACGAGTGGTGGAAATTTATACAGGTTGTTTGGTACTCTTC	480		
QY	482	ATACCTCGTGGATGTGGAATGAGCTACTGTCCTCCAAATCAAAAGTCTTAAATACTACTA	541		
Db	481	ATACCTCGTGGATGTGGAATGAGCTACTGTCCTCCAAATCAAAAGTCTTAAATACTACTA	540		
QY	542	TGTTTGCCAAATATTTGCTCCTGCTGTAATTTGGGCTAATAGACTATATGTCCTTATGAACA	601		
Db	541	TGTTTGCCAAATATTTGCTCCTGCTGTAATTTGGGCTAATAGACTATATGTCCTTATGAACA	600		
QY	602	AGGACACCTTGTGCCAGTTGCCAGATTAAGTGCAGATGAGCTATGACCAATGGTGG	661		
Db	601	AGGACACCTTGTGCCAGTTGCCAGATTAAGTGCAGATGAGCTATGACCAATGGTGG	660		
QY	662	CAAGTACGAAAGATCTCTATAGTAACTGTAAAGTTGAAGTGCACATTAACCTGTAAACA	721		
Db	661	CAAGTACGAAAGATCTCTATAGTAACTGTAAAGTTGAAGTGCACATTAACCTGTAAACA	720		

```

OY 722 TCAGTTGGTCAGGAGACAGTTCGACAGCATCTGCAATTTGTTCAACAGCATTTATTAAT 781
DB 721 TAGGTGGTCAGGAGAGTGGACAGGATCTGCAATTTGTTCAACAGCATTTATTAAT 780
OY 782 ACGCATTTACACACGAGTGGGCTATGTAGAGAGAGTACAGATTATCTACTAGATTG 841
DB 781 ACGCATTTACACACGAGTGGGCTATGTAGAGAGAGTACAGATTATCTACTAGATTG 840
OY 842 CATCTACTAGATTATTAACATATAGTACAGAAATTTAGAGCATGTTTATACACATTT 901
DB 841 CATCTACTAGATTATTAACATATAGTACAGAAATTTAGAGCATGTTTATACACATTT 900
OY 902 GATTTCGAATGTTTTCTCTGATCTGTTTTATTTTACAAAATATTTTTCATACA 961
DB 901 GATTTCGAATGTTTTCTCTGATCTGTTTTATTTTACAAAATATTTTTCATACA 960
OY 962 ATGTTTAAAAAGAACAAATCTATACACACAGTTGATTTTATATATAAGTTGT 1021
DB 961 ATGTTTAAAAAGAACAAATCTATACACACAGTTGATTTTATATATAAGTTGT 1020
OY 1022 GATTTTAAATTTACTGAAATTTAATAGGGTAAATTTTGAAGTTGTATTTTCATATGAC 1081
DB 1021 GATTTTAAATTTACTGAAATTTAATAGGGTAAATTTTGAAGTTGTATTTTCATATGAC 1080
OY 1082 TAAAGTCACTAAACCCGATTTGAAAGTAAATTTATGTTCTCTAGAACAAATGTACA 1141
DB 1081 TAAAGTCACTAAACCCGATTTGAAAGTAAATTTATGTTCTCTAGAACAAATGTACA 1140
OY 1142 AAAGAACATATATATTTTACATGACATGAAACCTTGCTGATGTTCCCTTCTACTCCAGTC 1201
DB 1141 AAAGAACATATATATTTTACATGACATGAAACCTTGCTGATGTTCCCTTCTACTCCAGTC 1200
OY 1202 TAAAGCTAGCATCTTCAAGACGTTTCCATATGCTGCTTAAATTTCTTTTCACTCAT 1261
DB 1201 TAAAGCTAGCATCTTCAAGACGTTTCCATATGCTGCTTAAATTTCTTTTCACTCAT 1260
OY 1262 CACCTTCTCCCAATCATCTGGTGGGATCTCTCAATTTAGTGTGAAGCTTCTCTCT 1321
DB 1261 CACCTTCTCCCAATCATCTGGTGGGATCTCTCAATTTAGTGTGAAGCTTCTCTCT 1320
OY 1322 AAAACAATCTGACATTTTATTTTGGCCAAATCAATACATCTTGAATTTTATCTGC 1381
DB 1321 AAAACAATCTGACATTTTATTTGGCCAAATCAATACATCTTGAATTTTATCTGC 1380
OY 1382 ATAAATTTTACATGATATGATCAAACTTCATTTTAAACCTCTCTCTTTTGACA 1441
DB 1381 ATAAATTTTACATGATATGATCAAACTTCATTTTAAACCTCTCTCTTTTGACA 1440
OY 1442 AAACCTCTTAAAAAAGATACAGATATATAGTAAATACCCCTCCACTCAAGAGGTA 1501
DB 1441 AAACCTCTTAAAAAAGATACAGATATATAGTAAATACCCCTCCACTCAAGAGGTA 1500
OY 1502 GAAGTCACTCTCTCTCTGAGTCTTCACTAAATCAGTACTCACTTCCAAAGAGTG 1561
DB 1501 GAAGTCACTCTCTCTCTGAGTCTTCACTAAATCAGTACTCACTTCCAAAGAGTG 1560
OY 1562 GAGTATGGAAGGAAACATAGTAACTTTACAGGGGAGAAAAATGACAAATGACGCTTTC 1621
DB 1561 GAGTATGGAAGGAAACATAGTAACTTTACAGGGGAGAAAAATGACAAATGACGCTTTC 1620
OY 1622 ACCAAGTATCAAAATTAAGTCACAGTGAATGATCAATTCAGATTTGTTCTAGATATC 1681
DB 1621 ACCAAGTATCAAAATTAAGTCACAGTGAATGATCAATTCAGATTTGTTCTAGATATC 1680
OY 1682 TTTCTAAAAATTCATATCCCAATCTAATATGAGCTAAACATCCAGCAAACTCAAGTT 1741
DB 1681 TTTCTAAAAATTCATATCCCAATCTAATATGAGCTAAACATCCAGCAAACTCAAGTT 1740
OY 1742 GAAGGACATTTACAAAATATCCCGGGGATTTTACAGTATCTCTCAAAACTGTAAAA 1801
DB 1741 GAAGGACATTTACAAAATATCCCGGGGATTTTACAGTATCTCTCAAAACTGTAAAA 1800

```

```

OY 1802 TCATGGAAAAATAGGGAATCTCTGAGAAACATCAGACACCATGAGACTAAGAGACAT 1861
DB 1801 TCATGGAAAAATAGGGAATCTCTGAGAAACATCAGACACCATGAGACTAAGAGACAT 1860
OY 1862 GTGAGCCAAATGCAATGTGCTCTTGGATCAGATCTCTGGAACAGAAAAAGATCAATATG 1921
DB 1861 GTGAGCCAAATGCAATGTGCTCTTGGATCAGATCTCTGGAACAGAAAAAGATCAATATG 1920
OY 1922 AAAAACTGATGATGCTGTAATGATGAGATGAGATATTTTAAACAGATGATGATTTCTT 1981
DB 1921 AAAAACTGATGATGCTGTAATGATGAGATGAGATATTTTAAACAGATGATGATTTCTT 1980
OY 1982 AATCTTGACAAATATAGCAGGTAATGTAAGATGATTAACGTTAGAGAAACTGAACTGG 2041
DB 1981 AATCTTGACAAATATAGCAGGTAATGTAAGATGATTAACGTTAGAGAAACTGAACTGG 2040
OY 2042 TGAGGGCTATCTAGGAATCTCTGATCTATCTTACCAATTTTCGGTAAAGTAAAG 2101
DB 2041 TGAGGGCTATCTAGGAATCTCTGATCTATCTTACCAATTTTCGGTAAAGTAAAG 2100
OY 2102 CAATGCAAAATATAAGATATCTTGAAAAA 2134
DB 2101 CAATGCAAAATATAAGATATCTTGAAAAA 2133

RESULT 3
AAH98659
ID AAH98659 standard; cDNA: 2133 BP.
AC AAH98659;
XX
DE 12-OCT-2001 (first entry)
XX
DE Human EST-derived coding sequence SEQ ID NO: 516.
XX
KW Human; sheep; pig; cow; fruit fly; yeast; hamster; macaque; horse;
KW tomato; monkey; dog; sea urchin; expressed sequence tag; EST;
KW diagnostics; forensic test; gene mapping; genetic disorder;
KW biodiversity; gene therapy; nutrition; ss.
XX
OS Homo sapiens.
XX
PN WO200154477-A2.
XX
PD 02-AUG-2001.
XX
PF 25-JAN-2001; 2001WO-US02687.
XX
PR 25-JAN-2000; 2000US-0491404.
PR 17-JUL-2000; 2000US-0617746.
PR 03-AUG-2000; 2000US-0631451.
PR 15-SEP-2000; 2000US-0663870.
XX
PA (HYSE-) HXSEQ INC.
XX
PI Tang YT, Liu C, Zhou P, Qian XB, Wang Z, Chen R, Asundi V;
PI Cao Y, Drmanac RA, Zhang J, Werhman T;
XX
DR WPI: 2001-476164/51.
XX
DR P-PSDB; AAM24000.
XX
PT Isolated polypeptide for treatment of diseases, diagnostics, raising
PT antibodies and research use.
XX
PS Claim 1; Page 537-538; 1275pp; English.
XX
CC The present invention provides the protein and coding sequences of novel
CC proteins from a variety of organisms, including human, dog, cat, horse,
CC cow, pig, hamster, monkey, macaque, yeast, bacteria, fruit fly, sea
CC urchin and tomato. These were derived from expressed sequence tags (ESTs)
CC from the organism of interest. They can be used in diagnostics,
CC forensics, gene mapping, identification of mutations, to assess
CC biodiversity and for nutritional purposes. The present sequence is a cDNA

```


Db 2041 TGAGGCTATCTAGCAATCTCTACTACTTCTACCAATTTTGGTAGCTAGAAGAAG 2100
 Oy 2102 CAATGCAAAATATAAAGTATCTTGAAAAAAA 2134
 |||||||
 Db 2101 CAATGCAAAATATAAAGTCTCAAAAAAAA 2133

RESULT 4
 ABL67806
 ID ABL67806 standard; DNA: 2128 BP.
 XX
 AC ABL67806;
 XX
 DT 15-MAY-2002 (first entry)
 XX
 DE Oesophagus cancer related gene sequence SEQ ID NO:6143.
 XX
 KM Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
 KM stomach; lung; prostate; pancreas; carcinoma; antitumor; cancerous;
 KM cytosolic; gene therapy; antineoplastic; Wilm's tumour; adenocarcinoma;
 KM gene; ds.
 XX
 OS Homo sapiens.
 XX
 PN MO200194629-A2.
 XX
 PD 13-DEC-2001.
 XX
 PF 30-MAY-2001; 2001WO-US10838.
 XX
 PR 05-JUN-2000; 2000US-209473P.
 PR 05-JUN-2000; 2000US-209531P.
 PR 18-SEP-2000; 2000US-233133P.
 PR 18-SEP-2000; 2000US-233617P.
 PR 20-SEP-2000; 2000US-234009P.
 PR 20-SEP-2000; 2000US-234034P.
 PR 20-SEP-2000; 2000US-234052P.
 PR 22-SEP-2000; 2000US-234509P.
 PR 22-SEP-2000; 2000US-234567P.
 PR 25-SEP-2000; 2000US-234923P.
 PR 25-SEP-2000; 2000US-234924P.
 PR 25-SEP-2000; 2000US-235077P.
 PR 25-SEP-2000; 2000US-235082P.
 PR 25-SEP-2000; 2000US-235134P.
 PR 25-SEP-2000; 2000US-235280P.
 PR 26-SEP-2000; 2000US-235637P.
 PR 26-SEP-2000; 2000US-235638P.
 PR 27-SEP-2000; 2000US-235711P.
 PR 27-SEP-2000; 2000US-235720P.
 PR 27-SEP-2000; 2000US-235840P.
 PR 27-SEP-2000; 2000US-235863P.
 PR 28-SEP-2000; 2000US-236028P.
 PR 28-SEP-2000; 2000US-236032P.
 PR 28-SEP-2000; 2000US-236033P.
 PR 28-SEP-2000; 2000US-236034P.
 PR 28-SEP-2000; 2000US-236109P.
 PR 28-SEP-2000; 2000US-236111P.
 PR 29-SEP-2000; 2000US-236842P.
 PR 29-SEP-2000; 2000US-236891P.
 PR 02-OCT-2000; 2000US-237172P.
 PR 02-OCT-2000; 2000US-237173P.
 PR 02-OCT-2000; 2000US-237284P.
 PR 02-OCT-2000; 2000US-237294P.
 PR 02-OCT-2000; 2000US-237295P.
 PR 03-OCT-2000; 2000US-237316P.
 PR 03-OCT-2000; 2000US-237425P.
 PR 03-OCT-2000; 2000US-237598P.
 PR 03-OCT-2000; 2000US-237604P.
 PR 03-OCT-2000; 2000US-237606P.
 PR 03-OCT-2000; 2000US-237608P.
 PR 01-NOV-2000; 2000US-244867P.
 PR 01-NOV-2000; 2000US-245084P.
 XX

PA (AVAL-) AVALON PHARM.
 XX
 XX Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrigan S;
 PI Soppet DR, Weaver Z;
 XX
 DR WPI: 2002-188264/24.
 XX
 PT Screening for anti-neoplastic agent involves exposing cells to a
 PT chemical agent to be tested for anti-neoplastic activity, and
 PT determining a change in expression of a gene of a signature gene set -
 XX
 PS Claim 1: SEQ ID 6143; 44pp; English.
 XX
 CC The present invention describes a method (M1) for screening for an
 CC anti-neoplastic agent. The method involves exposing cells to a chemical
 CC agent to be tested for anti-neoplastic activity, determining a change in
 CC expression of at least one gene (I) of a signature gene set, where (I)
 CC comprises a sequence (S) selected from 8447 sequences (given in ABL61864
 CC to ABL70110), or is at least 95% identical to (S), where a change in
 CC expression is indicative of anti-neoplastic activity. (I) has cytosolic
 CC activity and can be used in gene therapy. M1 can be used for screening
 CC an anti-neoplastic agent, and can be used for producing a product which
 CC is the data collected with respect to the anti-neoplastic agent as a
 CC result of M1, and the data is sufficient to convey the chemical
 CC structure and/or properties of the agent. M1 can be used in the
 CC treatment of cancer such as colon, breast, stomach, lung, thyroid,
 CC oesophageal, ovarian, kidney, prostate or pancreatic cancer,
 CC adenocarcinoma, carcinoma, clear cell cancer, infiltrating ductal cancer,
 CC infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine
 CC carcinoma, papillary carcinoma and Wilm's tumour.
 XX
 SQ Sequence 2128 BP; 734 A; 397 C; 380 G; 617 T; 0 other;
 Query Match 98.6%; Score 2113.2; DB 24; Length 2128;
 Best Local Similarity 99.9%; Pred. No. 0;
 Matches 2115; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 27 CTGGAACCACTGCAATGATATTCACAGTCTGTTGCTGCTGCTGCTT 86
 |||||||
 Db 1 CTGGAACCACTGCAATGATATTCACAGTCTGTTGCTGCTGCTGCTT 60
 Oy 87 CCATCTTTCCAGCAAAATGAAGATAGATCCGCTTTACTGCTTTTACCCCA 146
 |||||||
 Db 61 CCATCTTTCCAGCAAAATGAAGATAGATCCGCTTTACTGCTTTTACCCCA 120
 Oy 147 ACACAAGTCAAGGAGATGTAATGAAGCAATGAAGTGAAGAGAGAGATCTCC 206
 |||||||
 Db 121 ACACAAGTCAAGGAGATGTAATGAAGCAATGAAGTGAAGAGAGAGATCTCC 180
 Oy 207 CCTGCCAACAATCTGCAATGATGGAATGAAGCAAAAGGCTGCAAAATGCCCAAG 266
 |||||||
 Db 181 CCTGCCAACAATCTGCAATGATGGAATGAAGCAAAAGGCTGCAAAATGCCCAAG 240
 Oy 267 TGGGCAACCGTGAATTAAGACAGTAAACCAAGATCGAATGATGATGATGATG 326
 |||||||
 Db 241 TGGGCAACCGTGAATTAAGACAGTAAACCAAGATCGAATGATGATGATGATG 300
 Oy 327 TGTGCTGAGATCTCTACATGTCAGAGTCCCACTGATGTCAGAGATCCCAAGC 386
 |||||||
 Db 301 TGTGCTGAGATCTCTACATGTCAGAGTCCCACTGATGTCAGAGATCCCAAGC 360
 Oy 387 TGTGCTGAGATCTCTACATGTCAGAGTCCCACTGATGTCAGAGATCCCAAGC 446
 |||||||
 Db 361 TGTGCTGAGATCTCTACATGTCAGAGTCCCACTGATGTCAGAGATCCCAAGC 420
 Oy 447 GTTGACATTAATACACAGTGTGTTGAGTCTTCACTGATGATGATGATGATGATG 506
 |||||||
 Db 421 GTTGACATTAATACACAGTGTGTTGAGTCTTCACTGATGATGATGATGATGATG 480
 Oy 507 TACTGCTCAATCAAAAAGTCTAAATACTATGTTTCCCAATATGTTGCTGCTGCT 566
 |||||||
 Db 481 TACTGCTCAATCAAAAAGTCTAAATACTATGTTTCCCAATATGTTGCTGCTGCT 540

OY 567 AATTGGCTAATAGACTATATGTCCCTATGACAAAGGAGCCTGTGCCAGTTGCCCA 626
 DB 541 AATTGGCTAATAGACTATATGTCCCTATGACAAAGGAGCCTGTGCCAGTTGCCCA 600
 OY 627 GATACTGTGACGATGACATATGACCAATGTTGCAAGTACGAGATCTCTATAGTAAC 686
 DB 601 GATACTGTGACGATGACATATGACCAATGTTGCAAGTACGAGATCTCTATAGTAAC 660
 OY 687 TGTAAAGTTGAAAGCTCACAATTAACCTGTAAACATCACTGTTGGTGGAGGACGTTGCAAG 746
 DB 661 TGTAAAGTTGAAAGCTCACAATTAACCTGTAAACATCACTGTTGGTGGAGGACGTTGCAAG 720
 OY 747 GCATCCCTGCATTTGTTCAAAGAGCATTATTAATAGCATTAACACCGAGTAGGGCTA 806
 DB 721 GCCTCTGCATTTGTTCAAAGAGCATTATTAATAGCATTAACACCGAGTAGGGCTA 780
 OY 807 TGTAGAGAGAGTACGATTAATCTACTAGATTGGCATCTACTTATGATTAACTATATCT 866
 DB 781 TGTAGAGAGAGTACGATTAATCTACTAGATTGGCATCTACTTATGATTAACTATATCT 840
 OY 867 AGCTGAGAAATTTGAGCATGTTGATACACATTTGATTCAAAATGTTTCTCTGGAT 926
 DB 841 AGCTGAGAAATTTGAGCATGTTGATACACATTTGATTCAAAATGTTTCTCTGGAT 900
 OY 927 CTGCTTTTATTTTACAAAATATTTTTCATACAAATGTTTAAAGAAACAAATCTAT 986
 DB 901 CTGCTTTTATTTTACAAAATATTTTTCATACAAATGTTTAAAGAAACAAATCTAT 960
 OY 987 AACAACTTTGATTTTATATATTAATTAATTAATTAATTAATTAATTAATTAATTA 1046
 DB 961 AACAACTTTGATTTTATATATTAATTAATTAATTAATTAATTAATTAATTAATTA 1020
 OY 1047 GGGTGAATAATTTGAAAGTTGATTTCTATCTCATATGACTAAGTTCAAAACCTGATTTGA 1106
 DB 1021 GGGTGAATAATTTGAAAGTTGATTTCTATCTCATATGACTAAGTTCAAAACCTGATTTGA 1080
 OY 1107 AAGTGAATAATTTGCTCTAGACAAATGTTACAAAGAAACAAATTAATTTTCAATGA 1166
 DB 1081 AAGTGAATAATTTGCTCTAGACAAATGTTACAAAGAAACAAATTAATTTTCAATGA 1140
 OY 1167 ACCCTTGGCTAGTGTGCTTCTCTAGCTCCACTTAAGGCTAAGCATCTTCAAGAGCT 1226
 DB 1141 ACCCTTGGCTAGTGTGCTTCTCTAGCTCCACTTAAGGCTAAGCATCTTCAAGAGCT 1200
 OY 1227 TTTCCCATATGCTGTCTTAATTTCTTTTCACTCATTCACCTTCTTCCCATATCTGGCT 1286
 DB 1201 TTTCCCATATGCTGTCTTAATTTCTTTTCACTCATTCACCTTCTTCCCATATCTGGCT 1260
 OY 1287 GGCATCCCTACAAATGAGTGAAGCTGTTCCCTTAAACAAATCCTGACTTTTATTTTGC 1346
 DB 1261 GGCATCCCTACAAATGAGTGAAGCTGTTCCCTTAAACAAATCCTGACTTTTATTTTGC 1320
 OY 1347 CAAAATCAATCAATCTTTGAATTTTATCTGCATTAATTTTACAGTAGAATATGATC 1406
 DB 1321 CAAAATCAATCAATCTTTGAATTTTATCTGCATTAATTTTACAGTAGAATATGATC 1380
 OY 1407 AAACCTTATTTTAAACCTCTCTCTCTTTGACAAAACCTTCTTAAAGAAATATCAAG 1466
 DB 1381 AAACCTTATTTTAAACCTCTCTCTCTTTGACAAAACCTTCTTAAAGAAATATCAAG 1440
 OY 1467 ATATATATAGTAAATACCTCCACTCAAGAGAGTAGAACTGAGTCTCTGCTGTGAGAT 1526
 DB 1441 ATATATATAGTAAATACCTCCACTCAAGAGAGTAGAACTGAGTCTCTGCTGTGAGAT 1500
 OY 1527 CTTCACATAAATCAGTGAATCTTCAAAAGAGTGAATATGAAAGGAAACATATAGTA 1586
 DB 1501 CTTCACATAAATCAGTGAATCTTCAAAAGAGTGAATATGAAAGGAAACATATAGTA 1560
 OY 1587 CTTTACAGGGGAGAAATGACAAATGAGCTTTTACCAAGTATCAAAATTAAGTCTAC 1646
 DB 1561 CTTTACAGGGGAGAAATGACAAATGAGCTTTTACCAAGTATCAAAATTAAGTCTAC 1620
 OY 1647 CAGTGAATAAGTATCAGATTTGTTCTAGATATATCTTTTAAAAATTCATATATCCCAATC 1706

DB 1621 CAGTGAATAAGTATCAGATTTGTTCTAGATATCTTTTCTAAAAATCATATATCCCAATC 1680
 OY 1707 TAATATGAGCTAAACATATCCAGCAAACTCAAGTTGAAGAGCATTTCTACAAATATCCCT 1766
 DB 1681 TAATATGAGCTAAACATATCCAGCAAACTCAAGTTGAAGAGCATTTCTACAAATATCCCT 1740
 OY 1767 GGGCTATTTTAGATATCTCCCAAACTGTAATAATTCATGGAATATAGGGGAATCTCTGAG 1826
 DB 1741 GGGCTATTTTAGATATCTCCCAAACTGTAATAATTCATGGAATATAGGGGAATCTCTGAG 1800
 OY 1827 AAACATCAAGAGCAGATGAGACTAAGAGACATGTAGAGCCAAATGCAATGTCTTCTT 1886
 DB 1801 AAACATCAAGAGCAGATGAGACTAAGAGACATGTAGAGCCAAATGCAATGTCTTCTT 1860
 OY 1887 GGATCAGATCTGGAACAGAAAAGATCAGTAATGAAAAAACTGATGAATCTGATAGA 1946
 DB 1861 GGATCAGATCTGGAACAGAAAAGATCAGTAATGAAAAAACTGATGAATCTGATAGA 1920
 OY 1947 ATCTGAGTATTTTAAAGAGTGTGATTTCTTAATCTTGAACAATATAGCAGGCTAA 2006
 DB 1921 ATCTGAGTATTTTAAAGAGTGTGATTTCTTAATCTTGAACAATATAGCAGGCTAA 1980
 OY 2007 TGTAGATGATTAAGCTTGAAGAACTGAAACTGGGTGAGGCTATCTAGAAATCTCTGT 2066
 DB 1981 TGTAGATGATTAAGCTTGAAGAACTGAAACTGGGTGAGGCTATCTAGAAATCTCTGT 2040
 OY 2067 ACTATCTTACCAAAATTTTGGTAACTGTAAGAAACCAATGCAAAATTAAGATATCTGA 2126
 DB 2041 ACTATCTTACCAAAATTTTGGTAACTGTAAGAAACCAATGCAAAATTAAGATATCTGA 2100
 OY 2127 AAAAAAAAAAAAAAAAAA 2144
 DB 2101 AAAAAAAAAAAAAAAAAA 2118

RESULT 5
 ABV22644
 ID ABV22644 standard; cDNA: 2452 BP.
 XX
 AC ABV22644;
 XX
 DT 13-SEP-2002 (first entry)
 XX
 DE Human prostate expression marker cDNA 22635.
 XX
 KW Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;
 KW pharmacogenomic marker; gene; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200160860-A2.
 PD 23-AUG-2001.
 XX
 PE 20-FEB-2001; 2001WO-US05171.
 XX
 PR 17-FEB-2000; 2000US-183319P.
 PR 16-MAR-2000; 2000US-189862P.
 PR 25-MAY-2000; 2000US-207454P.
 PR 09-JUN-2000; 2000US-211314P.
 PR 18-JUL-2000; 2000US-219007P.
 PR 13-DEC-2000; 2000US-255281P.
 XX
 PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
 XX
 PI Schlegel R, Endege WO, Monahan JE;
 XX
 DR WPI; 2001-662795/76.
 XX
 PT Novel isolated nucleic acid molecule associated with cancerous state of
 PT prostate cells and correlating with presence of prostate cancer, useful
 PT for detecting presence of prostate cancer, stage of prostate cancer

XX Claim 1; Page 3969-3970; 11750pp; English.
 PS The invention relates to an isolated nucleic acid molecule (I) comprising
 XX a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the
 CC specification or its complement. (I) is useful for:
 CC (a) assessing whether a patient is afflicted with prostate cancer;
 CC (b) monitoring the progression of prostate cancer in a patient;
 CC (c) assessing the efficacy of a test compound to inhibit prostate
 CC cancer in a patient;
 CC (d) assessing the efficacy of a therapy for inhibiting prostate cancer
 CC in a patient;
 CC (e) selecting a composition for inhibiting prostate cancer in a patient;
 CC (f) assessing the prostate cell carcinogenic potential of a compound;
 CC (g) determining whether prostate cancer has metastasized in a patient;
 CC (h) assessing the aggressiveness or indolence of prostate cancer in a
 CC patient;
 CC (i) is also useful as a pharmacodynamic or pharmacogenomic marker.
 XX
 SQ Sequence 2452 BP; 787 A; 467 C; 444 G; 754 T; 0 other;
 Query Match 97.9%; Score 2100; DB 23; Length 2452;
 Best Local Similarity 99.8%; Pred. No. 0;
 Matches 2103; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 722 TCAGTTGGTCAGGACAGTTCGAAAGCATCTCGCAATTGTTCAACAGCATTATTAAT 781
 Db TCAGTTGGTCAGGACAGTTCGAAAGCATCTCGCAATTGTTCAACAGCATTATTAAT 975
 QY 782 ACGATTACACACGAGTAGAGGCTATGTAGAGAGAGTCATATTTACTAGATTGG 841
 Db ACGATTACACACGAGTAGAGGCTATGTAGAGAGAGTCATATTTACTAGATTGG 1035
 QY 842 CATCTACTAGATTATTAACATATAGCTGAGAAATGTAGCATGTTGTATACACATT 901
 Db CATCTACTAGATTATTAACATATAGCTGAGAAATGTAGCATGTTGTATACACATT 1095
 QY 902 GATTTCAAATGTTTCTTCGTGATCTGCTTTTATTTACAAAATATTTTCATCA 961
 Db GATTTCAAATGTTTCTTCGTGATCTGCTTTTATTTACAAAATATTTTCATCA 1155
 QY 962 ATGCTTAAAGAAACAAACCTATTAACACACTTTGGATTATATATTAACCTTGT 1021
 Db ATGCTTAAAGAAACAAACCTATTAACACACTTTGGATTATATATTAACCTTGT 1215
 QY 1022 GATTAAATTTACTGAATTTATAGGCTGAAATTTGAAAGTGTATTCATATGAC 1081
 Db GATTAAATTTACTGAATTTATAGGCTGAAATTTGAAAGTGTATTCATATGAC 1275
 QY 1142 AAAGAACATATATTTTCATATAGCCCTTGCTAGTGGCTTCTTACCTCCTC 1201
 Db AAAGAACATATATTTTCATATAGCCCTTGCTAGTGGCTTCTTACCTCCTC 1395
 QY 1202 TAAGCTAAGCATCTTCAAAAGACGTTTCCCATATGCTGTATTTCTTACATAT 1261
 Db TAAGCTAAGCATCTTCAAAAGACGTTTCCCATATGCTGTATTTCTTACATAT 1455
 QY 1262 CACCTTCTTCCCAATCATCTGCTGCGATCCTCACAATTAGTGAAGCTTCTCCT 1321
 Db CACCTTCTTCCCAATCATCTGCTGCGATCCTCACAATTAGTGAAGCTTCTCCT 1515
 QY 1322 AAACATCTGATCTTATTTTTCGCAAAATCAATACATCTTGAATTTTATCTGC 1381
 Db AAACATCTGATCTTATTTTTCGCAAAATCAATACATCTTGAATTTTATCTGC 1575
 QY 1382 ATAAATTTACAGTAGATATGATCAACCTTCAATTTTAACTCTCTCTTACA 1441
 Db ATAAATTTACAGTAGATATGATCAACCTTCAATTTTAACTCTCTCTTACA 1635
 QY 1442 AAATCTCTTAAAGAAATACAGATATATAGTAAATACCTCCACCTCAAGAGATA 1501
 Db AAATCTCTTAAAGAAATACAGATATATAGTAAATATACCTCCACCTCAAGAGATA 1695
 QY 1502 GAATCTAGTCTCTCCCTTGTGAGTCTTCAATAATCAGTACTCACTTCAAGAGTG 1561
 Db GAATCTAGTCTCTCCCTTGTGAGTCTTCAATAATCAGTACTCACTTCAAGAGTG 1755
 QY 1562 GAGTATGAAAGGAAACATAGTAACTTACAGGAGGAAAGAAATGACAATAGAGCTTTC 1621
 Db GAGTATGAAAGGAAACATAGTAACTTACAGGAGGAAAGAAATGACAATAGAGCTTTC 1815
 QY 1622 ACCAAGTATCAAAATTAAGTCAACGATGATAGTATTCAGATTTGTTCTAGATATC 1681
 Db ACCAAGTATCAAAATTAAGTCAACGATGATAGTATTCAGATTTGTTCTAGATATC 1875
 QY 1682 TTTTAAATTTCTAATCCCAATCTAATATGAGCTAAACATCAGCAAACTCAAGTT 1741
 Db TTTTAAATTTCTAATCCCAATCTAATATGAGCTAAACATCAGCAAACTCAAGTT 1935
 QY 1742 GAAGGACATTTCAAAATATCCCTGGGGTATTTTAAAGTATTCCTCAAAAGCTAATA 1801
 Db GAAGGACATTTCAAAATATCCCTGGGGTATTTTAAAGTATTCCTCAAAAGCTAATA 1995
 QY 1802 TCATGAAATTAAGGAATCCTGAGAAACATACAGACCATGAGACTAAGAGACAT 1861


```

|||||
Db 1996 TCATGGAAATTAAGGGAATCTCTGAGAAACATCACAGCCATGAGACTAAGGAGACAT 2055
Qy 1862 GTGAGCCAAATGCAATGCTCTCTTGGATCAGATCCTGGAAACAGAAAAAGATCACTAATG 1921
Db 2056 GTGAGCCAAATGCAATGCTCTCTTGGATCAGATCCTGGAAACAGAAAAAGATCACTAATG 2115
Qy 1922 AAAAACTGATGAAGTCTGCAATAGCAATCTGAGATTTTAAACAGTACTGTGATTCT 1981
Db 2116 AAAAAAGTGAAGTCTGCAATAGCAATCTGAGATTTTAAACAGTACTGTGATTCT 2175
Qy 1982 AATCTGCAATATAGCAGGTAATGTAGATGATTAACGTTAGAGAACTGAACCTGG 2041
Db 2176 AATCTGCAATATAGCAGGTAATGTAGATGATTAACGTTAGAGAACTGAACCTGG 2235
Qy 2042 TGAGGCTATCTAGGAATCTCTGACTATCTTACCAATTTTCGGTAAGTCTAAGAAAG 2101
Db 2236 TGAGGCTATCTAGGAATCTCTGACTATCTTACCAATTTTCGGTAAGTCTAAGAAAG 2295
Qy 2102 CATGCAA 2109
Db 2296 CAACTA 2303

RESULT 6
ABV24631
ID ABV24631 standard; CDNA: 2452 BP.
XX
AC ABV24631;
XX
DT 16-SEP-2002 (first entry)
XX
DE Human prostate expression marker CDNA 24622.
XX
KW Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;
XX
OS Homo sapiens.
XX
PN WO200160860-A2.
XX
PD 23-AUG-2001.
XX
PE 20-FEB-2001; 2001WO-US05171.
XX
PR 17-FEB-2000; 2000US-18319P.
PR 16-MAR-2000; 2000US-189862P.
PR 25-MAY-2000; 2000US-207454P.
PR 09-JUN-2000; 2000US-211314P.
PR 18-JUL-2000; 2000US-219007P.
PR 13-DEC-2000; 2000US-253281P.
XX
PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
PI Schlegel R, Endege WO, Monahan JE;
XX
WPI: 2001-662795/76.
XX
DR
XX
PT Novel isolated nucleic acid molecule associated with cancerous state of
PT prostate cells and correlating with presence of prostate cancer, useful
PT for detecting presence of prostate cancer, stage of prostate cancer
XX
PS Claim 1: Page 4680-4681; 11750pp; English.
XX
XX
XX The invention relates to an isolated nucleic acid molecule (I) comprising
XX a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the
XX specification or its complement. (I) is useful for:
XX (a) assessing whether a patient is afflicted with prostate cancer;
XX (b) monitoring the progression of prostate cancer in a patient;
XX (c) assessing the efficacy of a test compound to inhibit prostate
XX cancer in a patient;
XX (d) assessing the efficacy of a therapy for inhibiting prostate cancer
XX in a patient;

```

```

CC (e) selecting a composition for inhibiting prostate cancer in a patient;
CC (f) assessing the prostate cell carcinogenic potential of a compound;
CC (g) determining whether prostate cancer has metastasized in a patient;
CC (h) assessing the aggressiveness or indolence of prostate cancer in a
CC patient;
CC (i) is also useful as a pharmacodynamic or pharmacogenomic marker.
XX
SQ Sequence 2452 BP; 787 A; 467 C; 444 G; 754 T; 0 other:
Query Match 97.9%; Score 2100; DB 23; Length 2452;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 2103; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
Qy 2 GATGAACAAATCACTTCCTGCTGGAACCACTGCAATGACATTAATCCAGTCT 61
Db 196 GATGAACAAATCACTTCCTGCTGGAACCACTGCAATGACATTAATCCAGTCT 255
Qy 62 GTTGTTCCTGTTGCTGGGCTGCTTCCATCTTTTCAGCAATGAAGATAGATCCGC 121
Db 256 GTTGTTCCTGTTGCTGGGCTGCTTCCATCTTTTCAGCAATGAAGATAGATCCGC 315
Qy 122 TTTTACTGCTTTGTTAACCCCAACACACAGTGCAGAGGAGATTGTAATAGCACA 181
Db 316 TTTTACTGCTTTGTTAACCCCAACACAGTGCAGAGGAGATTGTAATAGCACA 375
Qy 182 TGAAGTGAAGAGAGATCTTCCCTCCCAAAACATGCTGAAGATGGAAGCAA 241
Db 376 TGAAGTGAAGAGAGATCTTCCCTCCCAAAACATGCTGAAGATGGAAGCAA 435
Qy 242 AGAGGCTGAGCAAAATGCCCAAAAGTGGGCAAAACAGTGCATTTACAGACAGTAACCC 301
Db 436 AGAGGCTGAGCAAAATGCCCAAAAGTGGGCAAAACAGTGCATTTACAGACAGTAACCC 495
Qy 302 AAAGATGCAATGACAAATCTAAATGTGGTGAATCTCTACATGTCAGATGCCCCAG 361
Db 496 AAAGATGCAATGACAAATCTAAATGTGGTGAATCTCTACATGTCAGATGCCCCAG 555
Qy 362 CTCATGTGCACAAGCAAAATCCAAAGCTGGTTGTGATGATCAATGATTTGACTTGTGT 421
Db 556 CTCATGTGCACAAGCAAAATCCAAAGCTGGTTGTGATGATCAATGATTTGACTTGTGT 615
Qy 422 AGGGCCAAAGACTCCCAACGCAAGTGTGGATTTATACACAGTTGTTGACTCTTC 481
Db 616 AGGGCCAAAGACTCCCAACGCAAGTGTGGATTTATACACAGTTGTTGACTCTTC 675
Qy 482 ATACCTGTTGGATGTGGAATGCTTACTGTCCCAATCAAAAAGTCTTAAATACTACTA 541
Db 676 ATACCTGTTGGATGTGGAATGCTTACTGTCCCAATCAAAAAGTCTTAAATACTACTA 735
Qy 542 TGTTCGCAATATGTCGCTGCTGTAATGGGCTAATAGACTATGTCCTTATGACA 601
Db 736 TGTTCGCAATATGTCGCTGCTGTAATGGGCTAATAGACTATGTCCTTATGACA 795
Qy 602 AGGAGCACTTGTGCAAGTGGCCAGATAGTGAAGATGAGATGACCAATGTTG 661
Db 796 AGGAGCACTTGTGCAAGTGGCCAGATAGTGAAGATGAGATGACCAATGTTG 855
Qy 662 CAAGTACGAAGATCTCTATAGTACTGTAAAGTTGAAGTCTACATTAACCTGTAACA 721
Db 856 CAAGTACGAAGATCTCTATAGTACTGTAAAGTTGAAGTCTACATTAACCTGTAACA 915
Qy 722 TCAGTGGTCAGGAGAGTGCAGAGCATCTGCATGTTCAACAGCATTTATTAAT 781
Db 916 TCAGTGGTCAGGAGAGTGCAGAGCATCTGCATGTTCAACAGCATTTATTAAT 975
Qy 782 ACGCATTAACACAGAGTAGGCTATGTAGAGAGAGTCAATATCTACTTATGATTTGG 841
Db 976 ACGCATTAACACAGAGTAGGCTATGTAGAGAGAGTCAATATCTACTTATGATTTGG 1035
Qy 842 CATCTACTTATGATTTAATATCTAGTGAAGATTTGAGCATGTTTATACACATTT 901
Db 1036 CATCTACTTATGATTTAATATCTAGTGAAGATTTGAGCATGTTTATACACATTT 1095

```

QY 902 GATTCAATGTTTTCTCTGATCGCTTTTATTTTACAAAATATTTTCATACAA 961
 |||||
 DB 1096 GATTCAAAATGTTTTCTCTGATCGCTTTTATTTTACAAAATATTTTCATACAA 1155
 |||||
 QY 962 ATGGTAAAAAGAACAAATCTATACAAACACTTTGGATTTTATATATAAACTTTGT 1021
 |||||
 DB 1156 ATGGTAAAAAGAACAAATCTATACAAACACTTTGGATTTTATATATAAACTTTGT 1215
 |||||
 QY 1022 GATTAAATTTAGGATTTAATTTAGGTAATAATTTGAAAGTGTATCTCATATGAC 1081
 |||||
 DB 1216 GATTAAATTTAGGATTTAATTTAGGTAATAATTTGAAAGTGTATCTCATATGAC 1275
 |||||
 QY 1082 TAAGTCATAAAACCTGGATGAAAGTAAATTTATGCTAGAACAAATGTACAA 1141
 |||||
 DB 1276 TAAGTCATAAAACCTGGATGAAAGTAAATTTATGCTAGAACAAATGTACAA 1335
 |||||
 QY 1142 AAAGAACATATATATTTTACATGAACCTGGCTAGTGGCTTCTAGCTCACATC 1201
 |||||
 DB 1336 AAAGAACATATATATTTTACATGAACCTGGCTAGTGGCTTCTAGCTCACATC 1395
 |||||
 QY 1202 TAAGGCTAAGCATCTTCAAGAGCTTTCCCATATGCTGCTTATTTCTTACATCAT 1261
 |||||
 DB 1396 TAAGGCTAAGCATCTTCAAGAGCTTTCCCATATGCTGCTTATTTCTTACATCAT 1455
 |||||
 QY 1262 CACCTTCTTCCCAATCATCTGGCTGGCATCTCACAAATGAGTGAAGCTGTTCCCT 1321
 |||||
 DB 1456 CACCTTCTTCCCAATCATCTGGCTGGCATCTCACAAATGAGTGAAGCTGTTCCCT 1515
 |||||
 QY 1322 AAAACAATCTGACTTTTATTTTGCACAAATCAATCAATCTTTGATTTTATCTGC 1381
 |||||
 DB 1516 AAAACAATCTGACTTTTATTTTGCACAAATCAATCAATCTTTGATTTTATCTGC 1575
 |||||
 QY 1382 ATAAATTTTACATAGATATGATCAAACTTATTTTAACTCTCTCTCTTGTGACA 1441
 |||||
 DB 1576 ATAAATTTTACATAGATATGATCAAACTTATTTTAACTCTCTCTCTTGTGACA 1635
 |||||
 QY 1442 AAATCTCTTAAAAAAGAAATACAGATATATATGATTAATACCTCCTCAGCAGAGGTA 1501
 |||||
 DB 1636 AAATCTCTTAAAAAAGAAATACAGATATATATGATTAATACCTCCTCAGCAGAGGTA 1695
 |||||
 QY 1502 GAACTAGTCTCTCCCTTGTGAGTCTTCACTAAAATCAAGTCACTTCCAAAAGTTC 1561
 |||||
 DB 1696 GAACTAGTCTCTCCCTTGTGAGTCTTCACTAAAATCAAGTCACTTCCAAAAGTTC 1755
 |||||
 QY 1562 GAGTATGGAAGGAAACATAGTACTTTACAGGAGAGAAAAATGACAAATGACGCTTC 1621
 |||||
 DB 1756 GAGTATGGAAGGAAACATAGTACTTTACAGGAGAGAAAAATGACAAATGACGCTTC 1815
 |||||
 QY 1622 ACCAAGTGAATTAATGAGTACAGATATGATCAATTTGTTCTGATATATC 1681
 |||||
 DB 1816 ACCAAGTGAATTAATGAGTACAGATATGATCAATTTGTTCTGATATATC 1875
 |||||
 QY 1682 TTTCTAATAATTCATATCCCATCTAATTTATGAGCTAAAACATCCAGCAAACTCAAGTT 1741
 |||||
 DB 1876 TTTCTAATAATTCATATCCCATCTAATTTATGAGCTAAAACATCCAGCAAACTCAAGTT 1935
 |||||
 QY 1742 GAAGGACATTTCAAAAATATCCCTGGGTATTTTATGAGTATTTCTCAAAACTGTAAAAA 1801
 |||||
 DB 1936 GAAGGACATTTCAAAAATATCCCTGGGTATTTTATGAGTATTTCTCAAAACTGTAAAAA 1995
 |||||
 QY 1802 TCATGAAAAATAGGAATCTGAGAAACATCACAGACACATGAGCTAAGGAGACAT 1861
 |||||
 DB 1996 TCATGAAAAATAGGAATCTGAGAAACATCACAGACACATGAGCTAAGGAGACAT 2055
 |||||
 QY 1862 GTGAGCAAAATGCAATGTCTCTTTGGATCAGATCCTGGAACAGAAAAAGATCAGTAATG 1921
 |||||
 DB 2056 GTGAGCAAAATGCAATGTCTCTTTGGATCAGATCCTGGAACAGAAAAAGATCAGTAATG 2115
 |||||
 QY 1922 AAAAAACATGATGAGCTGAATAGAAATCTGAGATATTTTAAACAGTATGATTTCTT 1981
 |||||
 DB 2116 AAAAAACATGATGAGCTGAATAGAAATCTGAGATATTTTAAACAGTATGATTTCTT 2175
 |||||
 QY 1982 AATCTTGACAAATATAGCAGGTAATGTAAAGATGATACGTTAGAGAACTGAACCTGGG 2041
 |||||

DB 2176 AATCTTGACAAATATAGCAGGTAATGTAAAGATGATACGTTAGAGAACTGAACCTGGG 2235
 |||||
 QY 2042 TGAGGGCTATCTAGGAATTTCTGCTACTATCTTACCAATTTTGGTAAAGTCTAAGAAAG 2101
 |||||
 DB 2236 TGAGGGCTATCTAGGAATTTCTGCTACTATCTTACCAATTTTGGTAAAGTCTAAGAAAG 2295
 |||||
 QY 2102 CAATGCAA 2109
 |||||
 DB 2296 CAACACTA 2303
 |||||

RESULT 7

ABV25272 standard; cDNA; 2452 BP.

ABV25272;

16-SEP-2002 (first entry)

Human prostate expression marker cDNA 25263.

Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;

pharmacogenomic marker; gene; ss.

Homo sapiens.

WO200160860-A2.

23-AUG-2001.

20-FEB-2001; 2001WO-US05171.

17-FEB-2000; 2000US-183319P.

16-MAR-2000; 2000US-189862P.

25-MAY-2000; 2000US-207454P.

09-JUN-2000; 2000US-211314P.

18-JUL-2000; 2000US-219007P.

13-DEC-2000; 2000US-255281P.

(MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.

Schlegel R, Endege WO, Monahan JE;

WPI: 2001-662795/76.

Claim 1: Page 4961; 11750pp; English.

The invention relates to an isolated nucleic acid molecule (I) comprising a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the specification or its complement. (I) is useful for:

- (a) assessing whether a patient is afflicted with prostate cancer;
- (b) monitoring the progression of prostate cancer in a patient;
- (c) assessing the efficacy of a test compound to inhibit prostate cancer in a patient;
- (d) assessing the efficacy of a therapy for inhibiting prostate cancer in a patient;
- (e) selecting a composition for inhibiting prostate cancer in a patient;
- (f) assessing the prostate cell carcinogenic potential of a compound;
- (g) determining whether prostate cancer has metastasized in a patient;
- (h) assessing the aggressiveness or indolence of prostate cancer in a patient;
- (i) is also useful as a pharmacodynamic or pharmacogenomic marker.

Sequence 2452 BP; 787 A; 467 C; 444 G; 754 T; 0 other;

Query Match: 97.9%; Score 2100; DB 23; Length 2452;

Best Local Similarity: 99.8%; Pred. No. 0; Mismatches 5; Indels 0; Gaps 0;
 Matches 2103; Conservative 0;

OY	2	GAGAAACAAATACCTTCATCCCTGCTCGTGAAGAACATCGAATGACATTTATCCCACTGCT	61
Db	196	GATGAAACAAATACCTTCATCCCTGCTCGTGAAGAACACTCGAATGACATTTATCCCACTGCT	255
OY	62	GTTGTTCTGTGTTGCTGGGCTGCTTCATCTTTTCCAGCAAAATGAAGATAAGGATCCCGC	121
Db	256	GTTGTTCTGTGTTGCTGGGCTGCTTCATCTTTTCCAGCAAAATGAAGATAAGGATCCCGC	315
OY	122	TTTTCCTGCTTGTATACCAACCCAAACAAATGCGAAAGGGAGATGTGAATAAGCAACA	181
Db	316	TTTTCCTGCTTGTATACCAACCCAAACAAAGGCAAGGAGGAGATGTGAATAAGCAACA	375
OY	182	TGAACTGAGAGAGAGATATCTCCCCCTCCAGAAACATGCTGAAAGATGGAAATGGAACAA	241
Db	376	TGAACTGAGAGAGAGATATCTCCCCCTCCAGAAACATGCTGAAAGATGGAAATGGAACAA	435
OY	242	AGAGCTGAGCAAAATGCCCAAAAGTGGGCAAAACGACGATTTACAGACACGATAACC	301
Db	436	AGAGCTGAGCAAAATGCCCAAAAGTGGGCAAAACGACGATTTACAGACACGATAACC	495
OY	302	AAAGATCGAAATGACAAAGCTATAAAATGTGGTGAATCTCTACATGTCAAGTCCCCAG	361
Db	496	AAAGATCGAAATGACAAAGCTATAAAATGTGGTGAATCTCTACATGTCAAGTCCCCAG	555
OY	362	CTCATGTGTCACAAAGCAATCCAAAGCTGTTTGATGATCAATGATTTTGACTTTGGTGT	421
Db	556	CTCATGTGTCACAAAGCAATCCAAAGCTGTTTGATGATCAATGATTTTGACTTTGGTGT	615
OY	422	AGGGCCAAAGACTCCCAACGACGATGGTTGGACATTTATACAGAGTTGTTGGTACTTTC	481
Db	616	AGGGCCAAAGACTCCCAACGACGATGGTTGGACATTTATACAGAGTTGTTGGTACTTTC	675
OY	482	ATACCTCGTTGATGTGGAATGCTTACTGTGCCAATCAAAAAGTTCTAAAAATACTACTA	541
Db	676	ATACCTCGTTGATGTGGAATGCTTACTGTGCCAATCAAAAAGTTCTAAAAATACTACTA	735
OY	542	TGTTTGCCCAATATGTGCGCTGCTGTAATGGGCTAATAGCTATATATGCTTCCCTATGACA	601
Db	736	TGTTTGCCCAATATGTGCTGCTGCTGTAATGGGCTAATAGCTATATATGCTTCCCTATGACA	795
OY	602	AGAGACACCTTGTCACAGTTGCCAGATACCTGTGACGATGAGCTATGACACCAATGGTTG	661
Db	796	AGAGACACCTTGTCACAGTTGCCAGATACCTGTGACGATGAGCTATGACACCAATGGTTG	855
OY	662	CAAGTACGAAGACTCTATATAGTACTGTAAAGTTGAGCTACATTAACCTGTAAACA	721
Db	856	CAAGTACGAAGACTCTATATAGTACTGTAAAGTTGAGCTACATTAACCTGTGTAAACA	915
OY	722	TCAGTTGGACAGGAGAGTGTGCAAGCATCTGCAATTTGTTCAACAGCAATTTTAAAT	781
Db	916	TCAGTTGGTCAGGAGACAGTTGTCAAGGCTCTGCAATTTGTTCAACAGCAATTTTAAAT	975
OY	782	ACGCATTACACACCGATAGGGCTATGTAGAGAGATCGATTTATCTACTTAGATTGG	841
Db	976	ACGCATTACACACCGATAGGGCTATGTAGAGAGATCGATTTATCTACTTAGATTGG	1035
OY	842	CATCTACTTATGATTTAACATATCTAGCTAGTGAATTTGTAGGCATGTTGTATACACTT	901
Db	1036	CATCTACTTATGATTTAACATATCTAGCTAGTGAATTTGTAGGCATGTTGTATACACTT	1095
OY	902	GATTTCAAAATGTTTCTCTGTGATCGCTTTTATTTACAAAAATTTTTCATACAA	961
Db	1096	GATTTCAAAATGTTTCTCTGTGATCGCTTTTATTTACAAAAATTTTTCATACAA	1155
OY	962	ATGGTTAAAAAGAACAAATCTATAACAACAACCTTTGATTTTATATATAAATCTTGT	1021
Db	1156	ATGGTTAAAAAGAACAAATCTATAACAACAACCTTTGATTTTATATATAAATCTTGT	1215
OY	1022	GATTTAAATTTACTGAATTTAATTAGGTTGAATTTTGAAGTTGTAATCTCATATGAC	1081
Db	1216	GATTTAAATTTACTGAATTTAATTAGGTTGAATTTTGAAGTTGTAATCTCATATGAC	1275

Oy	1082	TAAGTTCATAAAACCCGTGATTTGAAGGAAAATATAGTCTCTCGAACAAATGTACAA	1141
Db	1276	TAAGTTCATAAAACCCGTGATTTGAAGGAAAATATAGTCTCTCGAACAAATGTACAA	1335
Oy	1142	AAAGACAATATATATTTTCACATGAACCCCTTGCTGTAGTGCCTTCTCTAGCTCACTC	1201
Db	1336	AAAGACAATATATATTTTCACATGAACCCCTTGCTGTAGTGCCTTCTCTAGCTCACTC	1395
Oy	1202	TAAGGCTAAGCATCTTCAAAGACGTTTTCCCATATGCTGCTTAATCTCTTCACTCANT	1261
Db	1366	TAAGGCTAAGCATCTTCAAAGACGTTTTCCCATATGCTGCTTAATCTCTTCACTCANT	1455
Oy	1262	CACCCCTTCTCCCAATCATCTGGCTGGCATCCCTCACAAATGTAGTGAAGCTGTCTCCT	1321
Db	1456	CACCCCTTCTCCCAATCATCTGGCTGGCATCCCTCACAAATGTAGTGAAGCTGTCTCCT	1515
Oy	1322	AAACAATCTGAGCTTTATATTTTGCCAAATCAATACAACTCCTTGAAATTTTATCTGC	1381
Db	1516	AAACAATCTGAGCTTTATATTTTGCCAAATCAATACAACTCCTTGAAATTTTATCTGC	1575
Oy	1382	ATAAATTTTACGTGGAATATGATCAAACTTCATTTTAAACGCTCTCTCTTTGACA	1441
Db	1576	ATAAATTTTACGTGGAATATGATCAAACTTCATTTTAAACGCTCTCTCTTTGACA	1635
Oy	1442	AAACTTCCTTAAAAAAGAAATACAGATAATATAGTAATTAACCTTCACACTCAAGAGTA	1501
Db	1636	AAACTTCCTTAAAAAAGAAATACAGATAATATAGTAATTAACCTTCACACTCAAGAGTA	1695
Oy	1502	GAACTCAGTCCCTCTCCCTTGCTGAGTCTTACTATAATTCAGTACGTACGTCCAAAGAGT	1561
Db	1696	GAACTCAGTCCCTCTCCCTTGCTGAGTCTTACTATAATTCAGTACGTACGTCCAAAGAGT	1755
Oy	1562	GAGTATGAGAAAGGAACATAGTAATCTTACAGGGAGAGAAAAATGACAAATGACGTCTTC	1621
Db	1756	GAGTATGAGAAAGGAACATAGTAATCTTACAGGGAGAGAAAAATGACAAATGACGTCTTC	1815
Oy	1622	ACCAAGTATCAAAATTTAAACGTACCAAGTATAGTCATTTAGATTTGTTCTAGATAATC	1681
Db	1816	ACCAAGTATCAAAATTTAAACGTACCAAGTATAGTCATTTAGATTTGTTCTAGATAATC	1875
Oy	1682	TTTCTTAAATTCATATATCCCAATCTAATATAGAGTTAAACATCCAGAAACTCAAGTT	1741
Db	1876	TTTCTTAAATTCATATATCCCAATCTAATATAGAGTTAAACATCCAGAAACTCAAGTT	1935
Oy	1742	GAAAGCATTTCTACAAAAATATCCCTGGGGTATTTTAGAGTATTCTCTCAAAACGTATAAAA	1801
Db	1936	GAAAGCATTTCTACAAAAATATCCCTGGGGTATTTTAGAGTATTCTCTCAAAACGTATAAAA	1995
Oy	1802	TCATGGAATAATGAAGGAATCTGTAGAAACATACAGACACATGAGACTTAAGGACAT	1861
Db	1996	TCATGGAATAATGAAGGAATCTGTAGAAACATACAGACACATGAGACTTAAGGACAT	2055
Oy	1862	GTGAGCCAATGCAATGTGCTTCTTGATCAGATCCTGTGAAAGGAAAAAGATAGTAAG	1921
Db	2056	GTGAGCCAATGCAATGTGCTTCTTGATCAGATCCTGTGAAAGGAAAAAGATAGTAAG	2115
Oy	1922	AAAAAACTGATGAAGTCTGTAATGAAATCTGGAATATTTTAAACAGTAGTGATTTCTT	1981
Db	2116	AAAAAACTGATGAAGTCTGTAATGAAATCTGGAATATTTTAAACAGTAGTGATTTCTT	2175
Oy	1982	AATCTTGACAAATATAGCAGGGTAATGTAGATGATTAACGTTAGAGAACTGAACCTGGG	2041
Db	2176	AATCTTGACAAATATAGCAGGGTAATGTAGATGATTAACGTTAGAGAACTGAACCTGGG	2235
Oy	2042	TGAGGGCTATCTAGGAATCTCTGTACTATCTTAACCAAAATTTCCGTAATCTTAAGAAAG	2101
Db	2236	TGAGGGCTATCTAGGAATCTCTGTACTATCTTAACCAAAATTTCCGTAATCTTAAGAAAG	2295
Oy	2102	CAATGCAA 2109	
Db	2296	CAACACTA 2303	

XX	OS	Homo sapiens.	
XX	XX	WO200160860-A2.	
XX	PN		
XX	PD	23-AUG-2001.	
XX	XX		
PF	20-FEB-2001;	2001MO-US05171.	
XX	PR	17-FEB-2000;	2000US-183319P.
XX	PR	16-MAR-2000;	2000US-189862P.
PR	25-MAY-2000;	2000US-207454P.	
PR	09-JUN-2000;	2000US-211314P.	
PR	18-JUL-2000;	2000US-219007P.	
PR	13-DEC-2000;	2000US-235281P.	
XX	XX		
PA	(MILL-) MILENNIUM PREDICTIVE MEDICINE INC.		
XX	XX		
PI	Schlegel R, Endege WO, Monahan JE;		
XX	XX		
DR	WPI; 2001-662795/76.		
XX	XX		
PT	Novel isolated nucleic acid molecule associated with cancerous state of prostate cells and correlating with presence of prostate cancer, useful for detecting presence of prostate cancer, stage of prostate cancer		
PT	for detecting presence of prostate cancer, stage of prostate cancer		
XX	XX		
PS	Claim 1; Page 5942-5943; 11750pp; English.		
XX	XX		
CC	The invention relates to an isolated nucleic acid molecule (I) comprising a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the specification or its complement. (I) is useful for:		
CC	(a) assessing whether a patient is afflicted with prostate cancer;		
CC	(b) monitoring the progression of prostate cancer in a patient;		
CC	(c) assessing the efficacy of a test compound to inhibit prostate cancer in a patient;		
CC	(d) assessing the efficacy of a therapy for inhibiting prostate cancer in a patient;		
CC	(e) selecting a composition for inhibiting prostate cancer in a patient;		
CC	(f) assessing the prostate cell carcinogenic potential of a compound;		
CC	(g) determining whether prostate cancer has metastasized in a patient;		
CC	(h) assessing the aggressiveness or indolence of prostate cancer in a patient;		
CC	(I) is also useful as a pharmacodynamic or pharmacogenomic marker.		
CC	XX		
XX	Sequence 2452 BP; 787 A; 467 C; 444 G; 754 T; 0 other;		
XX	XX		
QY	Query Match	97.9%; Score 2100; DB 23; Length 2452;	
QY	Best Local Similarity	99.8%; Pred. No. 0;	
QY	Matches 2103; Conservative	0; Mismatches 5; Indels 0; Gaps 0;	
Db	2 GATGAACAACAACTACTCTTCCTGCTGGAACAACACTGCATGACATTATTCCTCAGTGT	61	
Db	196 GATGAACAACAACTACTCTTCCTGCTGGAACAACACTGCATGACATTATTCCTCAGTGT	255	
QY	62 GTTGTCTGCTGCTGCTGCTGCTGCTTCATCTTTCCAGCAATGAAGATAGATCCGC	121	
Db	256 GTTGTCTGCTGCTGCTGCTGCTGCTTCATCTTTCCAGCAATGAAGATAGATAGATCCGC	315	
QY	122 TTTTACTCTCTTTGTTAAACCCCAACCAACAGTGAAGGAGATTGGAAATTAACACAA	181	
Db	316 TTTTACTCTCTTTGTTAAACCCCAACCAACAGTGAAGGAGATTGGAAATTAACACAA	375	
QY	182 TGAAGTGAAGAGAGAGATATCTCCCTGCGCAACAATGCTGAAGATGAATGGAACAA	241	
Db	376 TGAAGTGAAGAGAGAGATATCTCCCTGCGCAACAATGCTGAAGATGAATGGAACAA	435	
QY	242 AGAGGCTGCACCAATGCCCCAAAAGTGGGCAAAACAGTGCATTAACAGACACAGTAACC	301	
Db	436 AGAGGCTGCACCAATGCCCCAAAAGTGGGCAAAACAGTGCATTAACAGACACAGTAACC	495	
QY	302 AAAAGATGGAATGACAACTTAAATGTGTGTGAGAAATCTCTACATGTCAAGTCCCCAG	361	
Db	496 AAAAGATGGAATGACAACTTAAATGTGTGTGAGAAATCTCTACATGTCAAGTCCCCAG	555	

PR 09-JUN-2000; 2000US-211314P.
PR 18-JUL-2000; 2000US-219007P.
PR 13-DEC-2000; 2000US-255281P.
XX
PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
XX Schlegel R, Endege WO, Monahan JE;
XX WPI; 2001-662795/76.
DR
XX Novel isolated nucleic acid molecule associated with cancerous state of
PT prostate cells and correlating with presence of prostate cancer, useful
PT for detecting presence of prostate cancer, stage of prostate cancer -
XX
PS Claim 1; Page 6006; 11750pp; English.
XX
CC The invention relates to an isolated nucleic acid molecule (I) comprising
CC a nucleotide sequence given in Tables 1-9 (ABV0010-ABV62213) of the
CC specification or its complement. (I) is useful for:
CC (a) assessing whether a patient is afflicted with prostate cancer;
CC (b) monitoring the progression of prostate cancer in a patient;
CC (c) assessing the efficacy of a test compound to inhibit prostate
CC cancer in a patient;
CC (d) assessing the efficacy of a therapy for inhibiting prostate cancer
CC in a patient;
CC (e) selecting a composition for inhibiting prostate cancer in a patient;
CC (f) assessing the prostate cell carcinogenic potential of a compound;
CC (g) determining whether prostate cancer has metastasized in a patient;
CC (h) assessing the aggressiveness or indolence of prostate cancer in a
CC patient;
CC (I) is also useful as a pharmacodynamic or pharmacogenomic marker.
XX
SQ Sequence 2452 Bp; 787 A; 467 C; 444 G; 754 T; 0 other:
Query Match 97.9%; Score 2100; DB 23; Length 2452;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 2103; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
QY 2 GATGAACAATATCTTCATCTGCTGCTGGAACCACTGCAATGATATTTCCAGTGT 61
DB 196 GATGAACAATATCTTCATCTGCTGCTGGAACCACTGCAATGATATTTCCAGTGT 255
QY 62 GTTGTCTCTGTGTGCTGCTGCTTCATCTTTCAGCAAAATGAGATAGATCCGC 121
DB 256 GTTGTCTCTGTGTGCTGCTGCTTCATCTTTCAGCAAAATGAGATAGATCCGC 315
QY 122 TTTTACTGCTTTGTTTAAACCAACCAACAGTGAAGGAGATTGTCAATAGACAA 181
DB 316 TTTTACTGCTTTGTTTAAACCAACCAACAGTGAAGGAGATTGTCAATAGACAA 375
QY 182 TGAATGAGAGAGAGATGTCCTCCCTGCGCAAAACATGCGAATGAGATGGAACAA 241
DB 376 TGAATGAGAGAGAGATGTCCTCCCTGCGCAAAACATGCGAATGAGATGGAACAA 435
QY 242 AGAGGCTGAGCAAAATGCCCAAAAGTGGCAAAACAGTCAATTTACAGACAGTAAACC 301
DB 436 AGAGGCTGAGCAAAATGCCCAAAAGTGGCAAAACAGTCAATTTACAGACAGTAAACC 495
QY 302 AAGAGTCAATGACAAATGCTAAATGCTGAGATGCTCTCAATGCAAGGCCCGAG 361
DB 496 AAGAGTCAATGACAAATGCTAAATGCTGAGATGCTCTCAATGCAAGGCCCGAG 555
QY 362 CTCATGTCGACAAAGCAATCAAAAGTGTGTTGATGATCAATGATTTGACTTGGGT 421
DB 556 CTCATGTCGACAAAGCAATCAAAAGTGTGTTGATGATCAATGATTTGACTTGGGT 615
QY 422 AGGGCCAAAGACTCCCAAGCAGTGTGACATTATACAGAGTGTGTTGACTCTTC 481
DB 616 AGGGCCAAAGACTCCCAAGCAGTGTGACATTATACAGAGTGTGTTGACTCTTC 675
QY 482 ATACCTCGTTGATGTGAAATGCTACGTCTCCCAATCAAAAGTCTAAATACTACTA 541
DB 676 ATACCTCGTTGATGTGAAATGCTACGTCTCCCAATCAAAAGTCTAAATACTACTA 735

QY 542 TGTTTGCCAATATGCTCTGCTGTAATTTGGGCTAATAGACTAATATGTCCTTATGAA 601
DB 736 TGTTTGCCAATATGCTCTGCTGTAATTTGGGCTAATAGACTAATATGTCCTTATGAA 795
QY 602 AGGAGCACCCTGTGCACTTGGCCAGATACGTGTACATGACATGATGACCAATGTTG 661
DB 796 AGGAGCACCCTGTGCACTTGGCCAGATACGTGTACATGACATGATGACCAATGTTG 855
QY 662 CAAGTACGAAATCTCTATGATGATGATGATGATGATGATGATGATGATGATGATG 721
DB 856 CAAGTACGAAATCTCTATGATGATGATGATGATGATGATGATGATGATGATGATG 915
QY 722 TCAGTTGGTCAAGGACAGTGTGCAAGCATCTGCAATGTTTCAACAGCATTATTAAT 781
DB 916 TCAGTTGGTCAAGGACAGTGTGCAAGCATCTGCAATGTTTCAACAGCATTATTAAT 975
QY 782 ACGCATTTACACCGAGTAGGCTATGTAGAGAGAGTCAATTTACTTACTAGTTGG 841
DB 976 ACGCATTTACACCGAGTAGGCTATGTAGAGAGAGTCAATTTACTTACTAGTTGG 1035
QY 842 CATCTACTAGATTAACATATACATAGCTGAGAAATTTGAGGATGTTGATACATTT 901
DB 1036 CATCTACTAGATTAACATATACATAGCTGAGAAATTTGAGGATGTTGATACATTT 1095
QY 902 GATTTCAATATGTTTCTGCTGATCTGCTTTTATTTTACAAAATATTTTTCATACAA 961
DB 1096 GATTTCAATATGTTTCTGCTGATCTGCTTTTATTTTACAAAATATTTTTCATACAA 1155
QY 962 ATGTTTAAAGCAAAATCTATATACACAACTTTGATTTTATATATTAATTTTGT 1021
DB 1156 ATGTTTAAAGCAAAATCTATATACACAACTTTGATTTTATATATTAATTTTGT 1215
QY 1022 GATTTTAAATTTCTGATATTTAATAGGCGAAATTTGAAAGTGTATTTTCATATGAC 1081
DB 1216 GATTTTAAATTTCTGATATTTAATAGGCGAAATTTGAAAGTGTATTTTCATATGAC 1275
QY 1082 TAGTTCACATAAACCTGATGTAAGTGAAGTGAATATATGTTCTTACAAACAAATG 1141
DB 1276 TAGTTCACATAAACCTGATGTAAGTGAAGTGAATATATGTTCTTACAAACAAATG 1335
QY 1142 AAGAACAATATATTTTACATGAACCTGTGGCTGTATGCTTCTGATGCTCAGTC 1201
DB 1336 AAGAACAATATATTTTACATGAACCTGTGGCTGTATGCTTCTGATGCTCAGTC 1395
QY 1202 TAAGGTAGCAATCTTCAAAAGCTTTTCCCATGCTGCTTAATCTTTTCACTCANT 1261
DB 1396 TAAGGTAGCAATCTTCAAAAGCTTTTCCCATGCTGCTTAATCTTTTCACTCANT 1455
QY 1262 CACCTCTCTCCCAATCATCTGCTGCAATCTGCAATGATGATGATGATGATGATG 1321
DB 1456 CACCTCTCTCCCAATCATCTGCTGCAATCTGCAATGATGATGATGATGATGATG 1515
QY 1322 AAAACAATCTGACTTTATTTTGGCAAAATCAATCAATCTTTGAATTTTATCTGC 1381
DB 1516 AAAACAATCTGACTTTATTTTGGCAAAATCAATCAATCTTTGAATTTTATCTGC 1575
QY 1382 ATTAATTTTACAGTATGATGATGATGATGATGATGATGATGATGATGATGATG 1441
DB 1576 ATTAATTTTACAGTATGATGATGATGATGATGATGATGATGATGATGATGATG 1635
QY 1442 AAACCTCTTAAAGAAATACAAAGATATATAGTAAATACCTTCACTCAAGAGGTA 1501
DB 1636 AAACCTCTTAAAGAAATACAAAGATATATAGTAAATACCTTCACTCAAGAGGTA 1695
QY 1502 GAATCTAGTCTCTCTCTGTGAGTCTTCACTAAATCACTGATCTCTCTCTCTCT 1561
DB 1696 GAATCTAGTCTCTCTCTGTGAGTCTTCACTAAATCACTGATCTCTCTCTCTCT 1755
QY 1562 GAGTATGAAAGGAAATAGTATGATTTTACAGGAGGAAATGACAAATGACGCTTC 1621
DB 1756 GAGTATGAAAGGAAATAGTATGATTTTACAGGAGGAAATGACAAATGACGCTTC 1815

OY 1622 ACCAAGTGAATCAAAATTAAGTCACAGTATGATTCAGATTTGTTCTAGATATC 1681
 DB 1816 ACCAAGTGAATCAAAATTAAGTCACAGTATGATTCAGATTTGTTCTAGATATC 1875
 OY 1682 TTTCTAAAATTCATATCCCAATCTAATTATGAGCTAAAACATCCAGCAACTCAAGT 1741
 DB 1876 TTTCTAAAATTCATATCCCAATCTAATTATGAGCTAAAACATCCAGCAACTCAAGT 1935
 OY 1742 GAAGGACATTCAGCAAAATATCCCGGGATTTTATGAGATTTCCCAAACTGTAATA 1801
 DB 1936 GAAGGACATTCAGCAAAATATCCCGGGATTTTATGAGATTTCCCAAACTGTAATA 1995
 OY 1802 TCATGGAAAAATAGGGAATCTCTGAGAAACATCACAGACCACATGAGACTAAGAGACAT 1861
 DB 1996 TCATGGAAAAATAGGGAATCTCTGAGAAACATCACAGACCACATGAGACTAAGAGACAT 2055
 OY 1862 GTGAGCCAAATGCAATGCTCTTCTTGATCAGATCCTGAGACAGAAAAAGATCAGTAATG 1921
 DB 2056 GTGAGCCAAATGCAATGCTCTTCTTGATCAGATCCTGAGACAGAAAAAGATCAGTAATG 2115
 OY 1922 AAAAACTGATGAGTCTGATAGAAATCTGAGATTTTAAACAGTATGATTTCTT 1981
 DB 2116 AAAAACTGATGAGTCTGATAGAAATCTGAGATTTTAAACAGTATGATTTCTT 2175
 OY 1982 AATCTTGACAAATATAGCAGGGTAATGATAGATTAACGTTAGAGAACTGAACTGGG 2041
 DB 2176 AATCTTGACAAATATAGCAGGGTAATGATAGATTAACGTTAGAGAACTGAACTGGG 2235
 OY 2042 TGAGGCTATCTAGGAATCTCTGATCTATCTTACCAATTTTCGGTAACTGTAAGAAAG 2101
 DB 2236 TGAGGCTATCTAGGAATCTCTGATCTATCTTACCAATTTTCGGTAACTGTAAGAAAG 2295
 OY 2102 CAATGCAA 2109
 DB 2296 CAACACTA 2303
 RESULT 11
 ABV24823
 ID ABV24823 standard; cDNA: 1610 BP.
 AC ABV24823;
 DT 16-SEP-2002 (first entry)
 DE Human prostate expression marker cDNA 24814.
 KW Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;
 KW pharmacogenomic marker; gene; ss.
 OS Homo sapiens.
 PN WO200160860-A2.
 PD 23-AUG-2001.
 PF 20-FEB-2001: 2001WO-US05171.
 PR 17-FEB-2000: 2000US-183319P.
 PR 16-MAR-2000: 2000US-189862P.
 PR 25-MAY-2000: 2000US-207454P.
 PR 09-JUN-2000: 2000US-211314P.
 PR 18-JUL-2000: 2000US-219007P.
 PR 13-DEC-2000: 2000US-255281P.
 PA (MIL-) MILLENNIUM PREDICTIVE MEDICINE INC.
 PI Schlegel R, Endege WO, Monahan JE;
 DR WPI, 2001-662795/76.
 PT Novel isolated nucleic acid molecule associated with cancerous state of prostate cells and correlating with presence of prostate cancer, useful

PT for detecting presence of prostate cancer, stage of prostate cancer -
 XX Claim 1: Page 4758-4759; 11750pp; English.
 PS
 CC The invention relates to an isolated nucleic acid molecule (1) comprising
 CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the
 CC specification or its complement. (1) is useful for:
 CC (a) assessing whether a patient is afflicted with prostate cancer;
 CC (b) monitoring the progression of prostate cancer in a patient;
 CC (c) assessing the efficacy of a test compound to inhibit prostate
 CC cancer in a patient;
 CC (d) assessing the efficacy of a therapy for inhibiting prostate cancer
 CC in a patient;
 CC (e) selecting a composition for inhibiting prostate cancer in a patient;
 CC (f) assessing the prostate cell carcinogenic potential of a compound;
 CC (g) determining whether prostate cancer has metastasized in a patient;
 CC (h) assessing the aggressiveness or indolence of prostate cancer in a
 CC patient;
 CC (i) is also useful as a pharmacodynamic or pharmacogenomic marker.
 XX
 SQ Sequence 1610 BP; 543 A; 292 C; 292 G; 483 T; 0 other;
 Query Match 52.7%; Score 1130.6; DB 23; Length 1610;
 Best Local Similarity 99.6%; Pred. No. 3.4e-210;
 Matches 1133; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 OY 2 GATGAACAAATACCTTCATCTGCTCTGGAACCACTGCATATGATTTTCCAGTGT 61
 DB 474 GATGAACAAATACCTTCATCTGCTCTGGAACCACTGCATATGATTTTCCAGTGT 533
 OY 62 GTTGTCTCGTGTGCTGGGCTGCTTCATCTTTCCAGCAATGAGATAGATCCGC 121
 DB 534 GTTGTCTCGTGTGCTGGGCTGCTTCATCTTTCCAGCAATGAGATAGATCCGC 593
 OY 122 TTTTACTGCTTTGTTAACCACCAACCACTGCAAGGGAGATTGCAATTAACACAA 181
 DB 594 TTTTACTGCTTTGTTAACCACCAACCACTGCAAGGGAGATTGCAATTAACACAA 653
 OY 182 TGAAGTGAAGAGAGAGATATCTCCCTCCGAAACATGCTGAAGATGGAATGGAACAA 241
 DB 654 TGAAGTGAAGAGAGAGATATCTCCCTCCGAAACATGCTGAAGATGGAATGGAACAA 713
 OY 242 AGAGGCTGACGCAATGCCCCCAAAAGTGGCAATGCAATTAACAGACAGTAAACC 301
 DB 714 AGAGGCTGACGCAATGCCCCCAAAAGTGGCAATGCAATTAACAGACAGTAAACC 773
 OY 302 AAAGGATCGAATGACAAAGCTTAAATGTGTGAGAAATCTCTCANGTCAAGTCCGCCAG 361
 DB 774 AAAGGATCGAATGACAAAGCTTAAATGTGTGAGAAATCTCTCANGTCAAGTCCGCCAG 833
 OY 362 CTCATGCTCACAAAGCAATCCAAAGCTGTTGATGAGTAAATGATTTGACTTTGGTGT 421
 DB 834 CTCATGCTCACAAAGCAATCCAAAGCTGTTGATGAGTAAATGATTTGACTTTGGTGT 893
 OY 422 AGGCCCAAGACTCCCAAGCAGAGTGTGACATTATACAGAGTGTGTTGGTACTTTC 481
 DB 894 AGGCCCAAGACTCCCAAGCAGAGTGTGACATTATACAGAGTGTGTTGGTACTTTC 953
 OY 482 ATACTGCTTGGATGTGGAATGCTACTGTCCTCAATCAAAAGTCTTAAATACTACTA 541
 DB 954 ATACTGCTTGGATGTGGAATGCTACTGTCCTCAATCAAAAGTCTTAAATACTACTA 1013
 OY 542 TGTGGCCAAATATGCTGCTGTAATTTGGCTTAATGACTATATGCTTATGGAACA 601
 DB 1014 TGTGGCCAAATATGCTGCTGTAATTTGGCTTAATGACTATATGCTTATGGAACA 1073
 OY 602 AGGAGCACTTGTGCACTGCTCCAGATAGTGTGAGCAGTATGACCAATGGTGTG 661
 DB 1074 AGGAGCACTTGTGCACTGCTCCAGATAGTGTGAGCAGTATGACCAATGGTGTG 1133
 OY 662 CAAGTAGCAAGATCTCTATAGTAAAGTTTGAAGTCACTTAACCTTAACA 721
 DB 1134 CAAGTAGCAAGATCTCTATAGTAAAGTTTGAAGTCACTTAACCTTAACA 1193

OY 722 TCAGTTGGTCAGGAGCAGTGTGCAGGACATCTGCAATTTGTCAACAGCATTTATTAAT 781
 DB 1194 TCAGTTGGTCAGGAGCAGTGTGCAGGACATCTGCAATTTGTCAACAGCATTTATTAAT 1253
 OY 782 ACGCATTTACACACGAGTAGGGCTATGTAGAGAGGAGTCAGATTATCTACTAGATTGG 841
 DB 1254 ACGCATTTACACACGAGTAGGGCTATGTAGAGAGGAGTCAGATTATCTACTAGATTGG 1313
 OY 842 CATCTACTAGATTATTAACATATACAGTACGAGAAATTTAGGCACTTTGATACATTT 901
 DB 1314 CATCTACTAGATTATTAACATATACAGTACGAGAAATTTAGGCACTTTGATACATTT 1373
 OY 902 GATTTCAATGTTTTCTCTGATCTGCTTTTATTTTACAAAATATTTTCATACAA 961
 DB 1374 GATTTCAATGTTTTCTCTGATCTGCTTTTATTTTACAAAATATTTTCATACAA 1433
 OY 962 ATGTTAAAAAGAAACAAATCTATTAACAACAACATTGGAATTTTATTAACCTTTGT 1021
 DB 1434 ATGTTAAAAAGAAACAAATCTATTAACAACAACATTGGAATTTTATTAACCTTTGT 1493
 OY 1022 GATTTAAATTTACTGAATTTAATTAAGGTGAAATTTTGAAGTGTATTCATATGAC 1081
 DB 1494 GATTTAAATTTACTGAATTTAATTAAGGTGAAATTTTGAAGTGTATTCATATGAC 1553
 OY 1082 TAAGTCACTAAACCCCTGGATGAAAGTAAATATGTCTCTAGAACAAATGTA 1138
 DB 1554 TAAGTCACTAAACCCCTGGATGAAAGTAAATATGTCTCTAGAACAAATGTA 1610

RESULT 12
 ABV38130/C
 ID ABV38130 standard: cDNA: 677 BP.

AC ABV38130:
 DT 16-SEP-2002 (first entry)
 XX Human prostate expression marker cDNA 38121.
 DE Human prostate expression marker cDNA 38121.
 KW Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;
 KM pharmacogenomic marker; gene: ss.
 XX Homo sapiens.
 OS
 XX WO200160860-A2.
 PN
 XX 23-AUG-2001.
 PD
 XX 20-FEB-2001; 2001WO-US05171.
 PF
 XX 17-FEB-2000; 2000US-183319P.
 PR 16-MAR-2000; 2000US-189862P.
 PR 25-MAY-2000; 2000US-207454P.
 PR 09-JUN-2000; 2000US-211314P.
 PR 18-JUL-2000; 2000US-219007P.
 PR 13-DEC-2000; 2000US-255281P.
 XX
 PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
 XX
 PI Schlegel R, Endege WO, Monahan JE;
 PI
 DR WPI; 2001-662795/76.
 XX
 XX Novel isolated nucleic acid molecule associated with cancerous state of
 PT prostate cells and correlating with presence of prostate cancer, useful
 PT for detecting presence of prostate cancer, stage of prostate cancer
 XX
 PS Claim 1; Page 7785; 11750pp; English.
 XX
 CC The invention relates to an isolated nucleic acid molecule (I) comprising
 CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the
 CC specification or its complement. (I) is useful for:

CC (a) assessing whether a patient is afflicted with prostate cancer;
 CC (b) monitoring the progression of prostate cancer in a patient;
 CC (c) assessing the efficacy of a test compound to inhibit prostate
 CC cancer in a patient;
 CC (d) assessing the efficacy of a therapy for inhibiting prostate cancer
 CC in a patient;
 CC (e) selecting a composition for inhibiting prostate cancer in a patient;
 CC (f) assessing the prostate cell carcinogenic potential of a compound;
 CC (g) determining whether prostate cancer has metastasized in a patient;
 CC (h) assessing the aggressiveness or indolence of prostate cancer in a
 CC patient;
 CC (i) is also useful as a pharmacodynamic or pharmacogenomic marker.

Sequence 677 BP; 170 A; 143 C; 127 G; 233 T; 4 other;

Query Match 26.6%; Score 569.4; DB 23; Length 677;
 Best Local Similarity 98.8%; Pred. No. 2.3e-101;
 Matches 592; Conservative 0; Mismatches 5; Indels 2; Gaps 2;

OY 1470 ATATAGTAATTAACCTCCACTCAAGAGTAGAACTCAGTCCCTGCTGACTCTT 1529
 DB 677 ATATAGTAATTAACCTCCACTCAAGAGTAGAACTCAGTCCCTGCTGACTCTT 618
 OY 1530 CACTAAATCAGTACTCCTCCAAAGAGTGTAGTGAAGGAAACATAGTACTT 1589
 DB 617 CACTAAATCAGTACTCCTCCAAAGAGTGTAGTGAAGGAAACATAGTACTT 558
 OY 1590 TACAGGGGAGAAATGACAAATGAGCTCTCCAGAGTGTCAAAATTAAGTCCACAG 1649
 DB 557 TACAGGGGAGAAATGACAAATGAGCTCTCCAGAGTGTCAAAATTAAGTCCACAG 498
 OY 1650 TGATAGCATTCAGATTTGTTCTAGATATCTTTCTAAAAATTCATTAATCCCATCTAA 1709
 DB 497 TGATAGCATTCAGATTTGTTCTAGATATCTTTCTAAAAATTCATTAATCCCATCTAA 438
 OY 1710 TTATGAGCTAAACATCCAGCAAACTCAAGTTTAAGGACATTTTACAAAATATCCTGGG 1769
 DB 437 TTATGAGCTAAACATCCAGCAAACTCAAGTTTAAGGACATTTTACAAAATATCCTGGG 378
 OY 1770 GTATTTAGAGTATTCCTCAAACTGTAAAAATCATGAAATTAAGGAATCCTGAGAA 1829
 DB 377 GTATTTAGAGTATTCCTCAAACTGTAAAAATCATGAAATTAAGGAATCCTGAGAA 318
 OY 1830 CAATCAGACACATAGAGTAAAGAGACATGTGAGCCAAATGCAATGTCTTGTGA 1889
 DB 317 CAATCAGACACATAGAGTAAAGAGACATGTGAGCCAAATGCAATGTCTTGTGA 258
 OY 1890 TCAGATCCTGGAGCAAAAAAGATCAATATGAAAAAATGATGAAGTCTGAATACATC 1949
 DB 257 TCAGATCCTGGAGCAAAAAAGATCAATATGAAAAAATGATGAAGTCTGAATACATC 198
 OY 1950 TGGAGTATTTTAAAGTAGTGTGATTTCTTAATCTTGAACAATATAGCAGGGTATGT 2009
 DB 197 TGGAGTATTTTAAAGTAGTGTGATTTCTTAATCTTGAACAATATAGCAGGGTATGT 140
 OY 2010 AAGATGTAACCTTAAGAAACTGAAACTGGGTAGAGGCTATCTAGAAATCTCTGTAC 2068
 DB 139 AAGATGTAACCTTAAGAAACTGAAACTGGGTAGAGGCTATCTAGAAATCTCTGTAC 81

RESULT 13
 ABV08220/C
 ID ABV08220 standard: cDNA: 676 BP.

AC ABV08220:
 DT 13-SEP-2002 (first entry)
 XX Human prostate expression marker cDNA 8211.
 DE Human prostate expression marker cDNA 8211.
 KW Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;
 KM pharmacogenomic marker; gene: ss.
 XX

